Clinical Trials
88 trialsA Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
West China Hospital
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
ReLIVE
Post Graduate Institute of Medical Education and Research, Chandigarh
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
IMPACT
Seattle Children's Hospital
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
INTERCEPT
Seattle Children's Hospital
GAP
Baylor College of Medicine
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Tongji Hospital
RIOT3
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
MTS105 for HCC
Peking University
OPTIM
Baylor College of Medicine
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
3D Printed Models for Liver Surgery
Zhejiang Cancer Hospital
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
NAC to Prevent Cisplatin-induced Hearing Loss
Children's Hospital Los Angeles
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
West China Hospital
Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy
Fudan University
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Changhai Hospital
Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies
Zhongnan Hospital
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
High Dose Rate Brachyablation of Primary Liver Lesions
University of Texas Southwestern Medical Center
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
M.D. Anderson Cancer Center
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Yale University
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Masonic Cancer Center, University of Minnesota
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Northwestern University
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
Xijing Hospital
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
Virginia Commonwealth University
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
University of Chicago